VKTX insider transaction filings
Viking Therapeutics, Inc. — 25 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-07. Screen VKTX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-07 | 4 | Kelly-Gemmell Dorothy Elizabeth — Director | Grant/award (A): 6,333 @ $0 · Grant/award (A): 40,800 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | ZANTE GREG — Chief Financial Officer | Grant/award (A): 31,667 @ $0 · Sale (S): 21,217 @ $33.47 | EDGAR |
| 2026-07-29 | 4 | Lian Brian — President & CEO, Director | Grant/award (A): 221,667 @ $0 · Sale (S): 148,517 @ $33.32 | EDGAR |
| 2026-07-29 | 4 | Mancini Marianna — Chief Operating Officer | Grant/award (A): 31,667 @ $0 · Sale (S): 18,217 @ $33.47 | EDGAR |
| 2026-06-03 | 4 | Chen Hubert C — Chief Medical Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Aubuchon Neil William — Chief Commercial Officer | Purchase (P): 4,475 @ $33.50 | EDGAR |
| 2026-01-26 | 4 | Aubuchon Neil William — Chief Commercial Officer | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Lian Brian — President & CEO, Director | Grant/award (A): 78,400 @ $0 · Grant/award (A): 224,080 @ $0 · Sale (S): 132,454 @ $32.29 · Sale (S): 53,279 @ $33.38 · Sale (S): 41,276 @ $34.22 · Sale (S): 6,400 @ $35.07 · +1 more | EDGAR |
| 2026-01-05 | 4 | Mancini Marianna — Chief Operating Officer | Grant/award (A): 41,000 @ $0 · Grant/award (A): 32,049 @ $0 · Sale (S): 31,961 @ $32.29 · Sale (S): 13,600 @ $33.37 · Sale (S): 10,500 @ $34.22 · Sale (S): 1,600 @ $35.07 · +1 more | EDGAR |
| 2026-01-05 | 4 | Rouan Sarah Kathryn — Director | Grant/award (A): 3,150 @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | MACARTNEY LAWSON — Director | Grant/award (A): 3,150 @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Rowland Charles A Jr — Director | Grant/award (A): 3,150 @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | ZANTE GREG — Chief Financial Officer | Grant/award (A): 41,000 @ $0 · Grant/award (A): 32,049 @ $0 · Sale (S): 31,961 @ $32.30 · Sale (S): 13,900 @ $33.38 · Sale (S): 10,300 @ $34.24 · Sale (S): 1,500 @ $32.09 · +1 more | EDGAR |
| 2026-01-05 | 4 | SINGLETON J MATTHEW — Director | Grant/award (A): 3,150 @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | FOEHR MATTHEW W — Director | Option exercise (M): 16,000 @ $3.33 · Sale (S): 16,000 @ $35.11 · Grant/award (A): 3,150 @ $0 · Option exercise (M): 16,000 (derivative) @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2025-10-28 | 4 | Mancini Marianna — Chief Operating Officer | Grant/award (A): 11,117 @ $0 · Sale (S): 6,185 @ $35.00 | EDGAR |
| 2025-10-28 | 4 | Lian Brian — President & CEO, Director | Grant/award (A): 70,084 @ $0 · Sale (S): 38,989 @ $35.01 | EDGAR |
| 2025-10-28 | 4 | Rowland Charles A Jr — Director | Grant/award (A): 16,000 @ $4.48 · Grant/award (A): 22,000 @ $5.80 · Grant/award (A): 22,000 @ $4.88 · Sale (S): 60,000 @ $35.57 · Option exercise (M): 16,000 (derivative) @ $0 · Option exercise (M): 22,000 (derivative) @ $0 · +1 more | EDGAR |
| 2025-10-28 | 4 | ZANTE GREG — Chief Financial Officer | Grant/award (A): 11,117 @ $0 · Sale (S): 6,185 @ $35.00 | EDGAR |
| 2025-07-03 | 4 | Lian Brian — President & CEO, Director | Grant/award (A): 48,333 @ $0 · Sale (S): 26,889 @ $27.80 | EDGAR |
| 2025-07-03 | 4 | Mancini Marianna — Chief Operating Officer | Grant/award (A): 7,667 @ $0 · Sale (S): 4,266 @ $27.77 | EDGAR |
| 2025-07-03 | 4 | ZANTE GREG — Chief Financial Officer | Grant/award (A): 7,667 @ $0 · Sale (S): 4,266 @ $27.76 | EDGAR |
| 2025-04-14 | 4 | FOEHR MATTHEW W — Director | Option exercise (M): 20,786 @ $8 · Option exercise (M): 20,786 (derivative) @ $0 | EDGAR |
| 2025-04-08 | 4/A | Rouan Sarah Kathryn — Director | Purchase (P): 1,240 @ $24.15 | EDGAR |
| 2025-04-02 | 4 | Rouan Sarah Kathryn — Director | Purchase (P): 1,240 @ $24.15 | EDGAR |
Recent 8-K events — Viking Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-22 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-19 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-27 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-23 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VKTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →